RNAi Company Ltd

Bunkyō-ku, Japan

RNAi Company Ltd

Bunkyō-ku, Japan

Time filter

Source Type

The presentation will be available under the "Investors – Presentations & Posters" section of the Company's website, www.rxipharma.com approximately 1 hour following the presentation. RXi's proprietary sd-rxRNA technology has many advantages over its competitors in the RNAi space.  Scientists at RXi have designed chemically-modified RNAi compounds with improved drug-like properties that are potent, stable and specific.  These proprietary compounds have built-in delivery properties and therefore do not require a delivery vehicle for local therapeutic applications.  The enhanced properties of sd-rxRNA include:  efficient spontaneous cellular uptake, stability, reduced potential for immune stimulation, and potent, long-lasting intracellular activity.  All cell types tested (primary, neuronal and non-adherent) internalize sd-rxRNA compounds uniformly and efficiently, resulting in potent and long lasting silencing.  sd‑rxRNA compounds have the ability to selectively block the expression of any target in the genome, thus providing applicability to a broad spectrum of therapeutic areas. RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs.  Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which has the ability to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition.  RXi developed a robust RNAi therapeutic platform including self-delivering RNA (sd-rxRNA) compounds that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas.  Our current programs include dermatology, ophthalmology and cell-based immunotherapy.  RXi's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas and we actively pursue research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies.  Additional information may be found on the Company's website, www.rxipharma.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors."  Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-3rd-annual-immuno-oncology-bdl-and-investment-forum-300462039.html


News Article | May 23, 2017
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of 5,000,000 shares of its common stock. In addition, Alnylam has granted the underwriter of the offering a 30-day option to purchase up to an additional 750,000 shares of its common stock solely to cover over-allotments. All of the shares in the offering are to be sold by Alnylam. Barclays Capital Inc. is acting as sole book-running manager for the offering. Alnylam intends to use the net proceeds from this offering for general corporate purposes, including clinical trial costs and other research and development expenses, continued growth of its manufacturing, quality, commercial and medical affairs capabilities to support its transition toward a commercial-stage biopharmaceutical company, working capital, capital expenditures and general and administrative expenses. The securities described above are being offered by Alnylam pursuant to an automatically effective shelf registration statement that Alnylam previously filed with the Securities and Exchange Commission (SEC). As a result of this offering, Alnylam no longer plans to participate in the previously scheduled UBS Global Healthcare conference tomorrow, May 24th. A registration statement (including a base prospectus) relating to these securities has been filed with the SEC and has become effective. Before you invest, you should read these and other documents Alnylam has filed with the SEC for more complete information about Alnylam and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. The offering will be made only by means of a preliminary prospectus supplement and related prospectus. Copies of the preliminary prospectus supplement and the final prospectus supplement, when available, and the accompanying base prospectus relating to the offering may be obtained by contacting Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; barclaysprospectus@broadridge.com (phone 888-603-5847). This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically-validated approach for the treatment of a wide range of debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including three product candidates that are in late-stage development or will be in 2017. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines. Alnylam Forward-Looking Statements Statements in this release concerning Alnylam's future expectations, plans and prospects, including, without limitation, statements about Alnylam’s proposed public offering, intended use of proceeds and Alnylam’s expectations regarding future company achievements, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, risks related to fluctuations in our stock price, those associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as those risks more fully discussed in the "Risk Factors" filed with Alnylam's most recent Quarterly Report on Form 10-Q filed with the SEC and in other filings that Alnylam makes with the SEC. There can be no assurance that Alnylam will be able to complete the proposed public offering on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.


News Article | May 24, 2017
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $71.87 per share. The gross proceeds to Alnylam from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $359.4 million. The offering is expected to close on or about May 30, 2017, subject to the satisfaction of customary closing conditions. In addition, Alnylam has granted the underwriter of the offering a 30-day option to purchase up to an additional 750,000 shares of its common stock solely to cover over-allotments. All of the shares in the offering are to be sold by Alnylam. Barclays Capital Inc. is acting as sole book-running manager for the offering. Alnylam intends to use the net proceeds from this offering for general corporate purposes, including clinical trial costs and other research and development expenses, continued growth of its manufacturing, quality, commercial and medical affairs capabilities to support its transition toward a commercial-stage biopharmaceutical company, working capital, capital expenditures and general and administrative expenses. The securities described above are being offered by Alnylam pursuant to an automatically effective shelf registration statement that Alnylam previously filed with the Securities and Exchange Commission (SEC). A registration statement (including a base prospectus) relating to these securities has been filed with the SEC and has become effective. Before you invest, you should read these and other documents Alnylam has filed with the SEC for more complete information about Alnylam and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. The offering will be made only by means of a preliminary prospectus supplement and related prospectus. Copies of the preliminary prospectus supplement and the final prospectus supplement, when available, and the accompanying base prospectus relating to the offering may be obtained by contacting Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; barclaysprospectus@broadridge.com (phone 888-603-5847). This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically-validated approach for the treatment of a wide range of debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including three product candidates that are in late-stage development or will be in 2017. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines. Alnylam Forward-Looking Statements Statements in this release concerning Alnylam's future expectations, plans and prospects, including, without limitation, statements about Alnylam’s proposed public offering, intended use of proceeds and Alnylam’s expectations regarding future company achievements, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, risks related to fluctuations in our stock price, those associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as those risks more fully discussed in the "Risk Factors" filed with Alnylam's most recent Quarterly Report on Form 10-Q filed with the SEC and in other filings that Alnylam makes with the SEC. There can be no assurance that Alnylam will be able to complete the proposed public offering on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of Jain PharmaBiotech's new report "RNAi - Technologies, Markets and Companies" to their offering. The markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials. The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development. Various markets relevant to RNAi are analyzed from 2016 to 2026. Markets are also analyzed according to technologies and use of siRNAs, miRNAs, etc. Various RNAi technologies are described, along with design and methods of manufacture of siRNA reagents. These include chemical synthesis by in vitro transcription and use of plasmid or viral vectors. Other approaches to RNAi include DNA-directed RNAi (ddRNAi) that is used to produce dsRNA inside the cell, which is cleaved into siRNA by the action of Dicer, a specific type of RNAse III. MicroRNAs are derived by processing of short hairpins that can inhibit the mRNAs. Expressed interfering RNA (eiRNA) is used to express dsRNA intracellularly from DNA plasmids. Regulatory, safety and patent issues are discussed. Side effects can result from unintended interaction between an siRNA compound and an unrelated host gene. If RNAi compounds are designed poorly, there is an increased chance for non-specific interaction with host genes that may cause adverse effects in the host. However, there are no major safety concerns and regulations are in preliminary stages as the clinical trials are still ongoing and there are no marketed products. Many of the patents are still pending. Profiles of 162 companies involved in developing RNAi technologies are presented along with 230 collaborations. They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery. Out of these, 33 are developing RNAi-based therapeutics and 36 are involved in microRNAs. The bibliography contains selected 650 publications that are cited in the report. The text is supplemented with 38 tables and 15 figures. For more information about this report visit http://www.researchandmarkets.com/research/5nz4nw/rnai


News Article | April 18, 2017
Site: www.the-scientist.com

A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool?


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of Jain PharmaBiotech's new report "Antiviral Therapeutics - Technologies, Markets and Companies" to their offering. This report reviews the current state-of-art of antiviral approaches including vaccines, pharmaceuticals and innovative technologies for delivery of therapeutics. The introduction starts with a practical classification of viral diseases according to their commercial importance. Various antiviral approaches are described including pharmaceuticals and molecular biological therapies such as gene therapy and RNA interference (RNAi) as well as vaccines for virus infections. Expert opinion is given about the current problems and needs in antiviral therapy. SWOT (strengths, weaknesses, opportunities and threats) analysis of antiviral approaches is presented against the background of concept of an ideal antiviral agent. A novel feature of this report is the use of nanotechnology in virology and its potential for antiviral therapeutics. Interaction of nanoparticles with viruses are described. NanoViricides are polymeric micelles, which act as nanomedicines to destroy viruses. Various methods for local as well as systemic delivery of antiviral agents and vaccines are described. Nanobiotechnology plays an important role in improving delivery of antivirals. Advantages and limitations of delivery of gene-based, antisense and RNAi antiviral therapeutics are discussed. After a discussion of current therapies of AIDS/HIV and their limitations, new strategies in development of antiviral agents are described. Drug resistance and toxicities are emerging as major treatment challenges. Based on a review of technologies and drugs in development, it can be stated that there are good prospects are of finding a cure for HIV/AIDS in the next decade. Hepatitis viruses are described with focus on hepatitis C virus (HCV) and hepatitis B virus (HBV). Despite the presence of numerous drug candidates in the anti-HCV pipeline, and the commitment of major R&D resources by many pharmaceutical companies, it might still take several years for any new anti-HCV drugs to reach the market. Various commercially important viruses include herpes simplex (HSV) and human papilloma virus (HPV). There a number of treatments but HSV is not destroyed completely and remains dormant and activates from time to time to cause various clinical manifestations. There is discussion about the role of HPV in cervical cancer and vaccines available now seem to be adequate in preventing HSV-induced cervical cancer. Markets for antivirals are considered according to viruses and diseases caused by them and also according to management approaches: antiviral drugs, vaccines, MAbs and innovative approaches that include immunological and use of other technologies such as gene therapy, antisense, RNAi and nanobiotechnology. Antiviral markets are estimated starting with 2016 with projections up to the year 2026. Profiles of 194 companies that are involved in developing various technologies and products are profiled and with 174 collaborations. These include major pharmaceutical companies (12), Biopharmaceutical companies with antiviral products (86), Antiviral drug companies (26) as well as viral vaccine companies (70). The report is supplemented with 53 tables, 15 figures and 550 references from the literature. For more information about this report visit http://www.researchandmarkets.com/research/38qv7h/antiviral


Global Nanotechnology Drug Delivery Systems Market by Technologies, Applications, Growth Trends and Forecast to 2021, New Report by iHealthcareAnalyst, Inc. Nanotechnology Drug Delivery Systems Market by Technology Types (Nanocrystals, Nanoparticles, Dendrimers, Gold Nanoparticles, Fullerenes, Liposomes, Micelles, Nanotubes), and Applications (Anti-Infective, Anti-Inflammatory, Immunology, Cardiovascular, Physiology, Neurology, Oncology) and Forecast 2017-2021 Maryland Heights, MO, April 28, 2017 --( Browse Nanotechnology Drug Delivery Systems Market by Technology Types (Nanocrystals, Nanoparticles, Dendrimers, Gold Nanoparticles, Fullerenes, Liposomes, Micelles, Nanotubes), and Applications (Anti-Infective, Anti-Inflammatory, Immunology, Cardiovascular, Physiology, Neurology, Oncology) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/nanotechnology-drug-delivery-systems-market/ The global nanotechnology drug delivery systems market segmentation is based on technology types (nanocrystals, nanoparticles, dendrimers, gold nanoparticles, fullerenes, liposomes, micelles, nanotubes), and its applications (anti-infective, anti-inflammatory, immunology, cardiovascular, physiology, neurology, oncology). The global nanotechnology drug delivery systems market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021). The global nanotechnology drug delivery systems market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global nanotechnology drug delivery systems market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. Major players operating in the global nanotechnology drug delivery systems market and included in this report are AbbVie, Amgen, Celgene Corporation, Elan Pharmaceuticals, Johnson & Johnson, Pfizer, Inc., Merck & Co., Novartis AG, and Teva Pharmaceuticals. 1. Technology 1.1. Nanocrystals 1.2. Nanoparticles 1.3. Dendrimers 1.4. Gold Nanoparticles 1.5. Fullerenes 1.6. Liposomes 1.7. Micelles 1.8. Nanotubes 1.9. Others 2. Application 2.1. Anti-infective 2.2. Anti-inflammatory/Immunology 2.3. Cardiovascular/Physiology 2.4. Neurology 2.5. Oncology 2.6. Others 3. Geography (Region, Country) 3.1. North America (U.S., Canada) 3.2. Latin America (Brazil, Mexico, Rest of LA) 3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 3.4. Asia Pacific (Japan, China, India, Rest of APAC) 3.5. Rest of the World 4. Company Profiles 4.1. AbbVie, Inc. 4.2. Amgen Inc. 4.3. Celgene Corporation 4.4. Johnson & Johnson 4.5. Merck & Co., Inc. 4.6. Novartis International AG 4.7. Perrigo Company plc 4.8. Pfizer, Inc. 4.9. Teva Pharmaceutical Industries Ltd. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/nanotechnology-drug-delivery-systems-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, April 28, 2017 --( PR.com )-- Nanotechnology drug delivery systems involve the engineering of functional systems at the molecular scale, characterized by unique physical, optical and electronic features. Nanomedicine is a highly specific medical intervention for the prevention, diagnosis and treatment of diseases. Several anti-cancer drugs including paclitaxel, doxorubicin, 5-fluorouracil and dexamethasone have been successfully formulated using nanomaterials. Quantom dots, chitosan, Polylactic or glycolic acid (PLGA) and PLGA-based nanoparticles have also been used for in vitro RNAi delivery. The ability of nanotechnology to provide targeted drug delivery, improved solubility, extended half-life and reduce a drug’s immunogenicity has resulted in the potential to revolutionize the treatment of many diseases. Over the last two decades, significant progress has been made in the field of nanomedicine, resulting in a number of products, including therapeutics and imaging agents, enabling more effective and less toxic therapeutic and diagnostic interventionsBrowse Nanotechnology Drug Delivery Systems Market by Technology Types (Nanocrystals, Nanoparticles, Dendrimers, Gold Nanoparticles, Fullerenes, Liposomes, Micelles, Nanotubes), and Applications (Anti-Infective, Anti-Inflammatory, Immunology, Cardiovascular, Physiology, Neurology, Oncology) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/nanotechnology-drug-delivery-systems-market/The global nanotechnology drug delivery systems market segmentation is based on technology types (nanocrystals, nanoparticles, dendrimers, gold nanoparticles, fullerenes, liposomes, micelles, nanotubes), and its applications (anti-infective, anti-inflammatory, immunology, cardiovascular, physiology, neurology, oncology). The global nanotechnology drug delivery systems market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021). The global nanotechnology drug delivery systems market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global nanotechnology drug delivery systems market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.Major players operating in the global nanotechnology drug delivery systems market and included in this report are AbbVie, Amgen, Celgene Corporation, Elan Pharmaceuticals, Johnson & Johnson, Pfizer, Inc., Merck & Co., Novartis AG, and Teva Pharmaceuticals.1. Technology1.1. Nanocrystals1.2. Nanoparticles1.3. Dendrimers1.4. Gold Nanoparticles1.5. Fullerenes1.6. Liposomes1.7. Micelles1.8. Nanotubes1.9. Others2. Application2.1. Anti-infective2.2. Anti-inflammatory/Immunology2.3. Cardiovascular/Physiology2.4. Neurology2.5. Oncology2.6. Others3. Geography (Region, Country)3.1. North America (U.S., Canada)3.2. Latin America (Brazil, Mexico, Rest of LA)3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)3.4. Asia Pacific (Japan, China, India, Rest of APAC)3.5. Rest of the World4. Company Profiles4.1. AbbVie, Inc.4.2. Amgen Inc.4.3. Celgene Corporation4.4. Johnson & Johnson4.5. Merck & Co., Inc.4.6. Novartis International AG4.7. Perrigo Company plc4.8. Pfizer, Inc.4.9. Teva Pharmaceutical Industries Ltd.To request Table of Contents and Sample Pages of this report visit:https://www.ihealthcareanalyst.com/report/nanotechnology-drug-delivery-systems-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com


A double-stranded nucleic acid molecule including (a) a sense strand which includes a nucleotide sequence corresponding to a target sequence indicated by any one of SEQ ID Nos.: 1 to 21, and (b) an antisense strand which includes a nucleotide sequence complementary to that of the sense strand specified in (a), wherein the double-stranded nucleic acid molecule is for suppressing the expression of at least one of APP and EBAG9 genes.


The present invention aims to provide a double-stranded nucleic acid molecule (e.g., siRNA) which can effectively inhibit the proliferation of uterine, breast and bladder cancer cells by suppressing the expression of at least one target gene of COX7RP and Efp genes (estrogen-responsive genes); a cancer cell proliferation inhibitor; and a pharmaceutical agent. Specifically, the present invention relates to a double-stranded nucleic acid molecule for suppressing the expression of at least one of COX7RP and Efp genes which includes (a) a sense strand which includes a nucleotide sequence corresponding to a target sequence indicated by any one of SEQ ID Nos.: 1 to 38 and (b) an antisense strand which includes a nucleotide sequence complementary to that of the sense strand specified in (a); a cancer cell proliferation inhibitor with the double-stranded nucleic acid molecule and against at least one of uterine, breast and bladder cancer cells; and a pharmaceutical agent with the cancer cell proliferation inhibitor and against at least one of uterine, breast and bladder cancers.


A double-stranded nucleic acid molecule including (a) a sense strand which includes a nucleotide sequence corresponding to a target sequence indicated by any one of SEQ ID Nos.: 1 to 21, and (b) an antisense strand which includes a nucleotide sequence complementary to that of the sense strand specified in (a), wherein the double-stranded nucleic acid molecule is for suppressing the expression of at least one of APP and EBAG9 genes.

Loading RNAi Company Ltd collaborators
Loading RNAi Company Ltd collaborators